市场调查报告书
商品编码
1262674
临床前 CRO 市场——按服务(生物分析和 DMPK 试验、毒理学试验)、按最终用户(生物製药公司、政府和学术机构、医疗器械公司)、按地区和全球预测,2023-2032 年Preclinical CRO Market - By Service (Bioanalysis & DMPK Studies, Toxicology Testing), By End-use (Biopharmaceutical Companies, Government & Academic Institutes, Medical Device Companies), By Region & Global Forecast, 2023 - 2032 |
临床前 CRO 市场将在 2032 年稳步增长,因为慢性病的增加和对有效治疗的需求不断增加预计会推动临床前研究中药物使用的增加。
此外,生物技术和製药公司通常选择外包来满足他们在临床前试验中的医疗需求,从而加快整个过程。 为此,进入临床前阶段的药物数量显着增加。
总体而言,临床前 CRO 市场在最终用途、服务和地域方面存在分歧。
在服务领域,“其他”子领域预计在估计期内将保持超过 7% 的复合年增长率的稳定增长率。 临床前CRO市场的其他服务包括生物利用度研究、生物等效性研究、药物相互作用研究服务等。
临床前 CRO 市场根据最终用途细分为政府/学术机构、生物製药公司、医疗设备公司等。 其中,政府和学术机构部门将在 2022 年占据超过 14.5% 的市场份额。 这种增长主要归因于委託给学术机构的研究和调查活动数量的增加。 学术机构和政府也正在提供临床前诊断和治疗的途径,这将推动未来临床前 CRO 行业的发展。
按地区划分,临床前 CRO 市场大致分为北美、欧洲、亚洲格局、市场格局和亚太地区。 其中,亚太地区临床前CRO市场有望在预测期内实现稳定增长。 该地区老年人口的增加,糖尿病、癌症、心脏病等慢性病患病率的增加,预计将补充市场增长。
此外,亚太地区肿瘤领域的研究药物和正在进行的临床前试验的数量正在增加,这有望推动该地区临床前 CRO 业务的规模。
另一方面,拉美地区的临床前 CRO 市场预计在分析期内也将出现强劲增长。 该地区拥有发达的医疗保健基础设施和成熟的监管环境。 这些因素使拉丁美洲成为临床前研究的沃土。
在临床前 CRO 市场运营的领先公司包括:Laboratory Corporation of America Inc.、Charles River Laboratory Inc.、Pharmaceutical Product Development. (PPD) LLC、ICON plc、Eurofins Scientific、Parexel International Corporation, Medpace, WuXi AppTec, SGS SA, Altasciences Company, Inc.
Preclinical CRO Market is slated to grow at a robust rate through 2032 owing to the increasing usage of drugs during preclinical trials given the rising cases of chronic diseases and an increasing demand for effective treatment for the same. Besides, various biotechnology and pharmaceutical companies, quite often, opt for outsourcing to attain the medical needs for preclinical validations to fasten up the whole process. This has significantly propelled the number of drugs entering the preclinical phase.
Overall, the preclinical CRO market has been bifurcated in terms of end-use, service, and region.
Within the service segment, the others subsegment is slated to grow at a steady rate of more than 7% CAGR through the estimated timeframe. The other services in the preclinical CRO market comprise bioavailability testing, bioequivalence testing, drug-interaction testing services, etc.
Based on end-use, the preclinical CRO market has been divided into government & academic institutes, biopharmaceutical companies, medical device companies, and others. Among them, the government & academic institutes segment held more than 14.5% market share in 2022. The growth can be primarily attributed to the increasing number of research and R&D activities that are outsourced to academic institutes. Besides, academic institutes and the governments are also providing diagnosis and access to treatments under preclinical trials, which is likely to propel the preclinical CRO industry growth in the upcoming time.
In the regional landscape, the preclinical CRO market has been broadly categorized into North America, Europe, LATAM, MEA, and Asia Pacific. Among them, the preclinical CRO market in the Asia Pacific region is anticipated to grow at a steady rate over the estimated timeframe. The increasing geriatric population in this region and rising cases of chronic diseases like diabetes, cancer, and cardiac diseases are anticipated to supplement the market growth.
Additionally, an increase in the number of investigational compounds and ongoing preclinical trials in oncology in Asia Pacific will boost the preclinical CRO business size in this region.
Meanwhile, the preclinical CRO market in the LATAM region is also slated to grow at a robust rate through the analysis timeframe. The healthcare infrastructure in this region is well-developed and it also boasts a well-established regulatory environment. These factors enable Latin America to be a fertile landscape to allow preclinical research to be conducted easily.
Some of the key companies operating in the preclinical CRO market are: Laboratory Corporation of America Inc., Charles River Laboratory Inc., Pharmaceutical Product Development (PPD) LLC, ICON plc, Eurofins Scientific, Parexel International Corporation, Medpace, Inc., WuXi AppTec, SGS SA, Altasciences Company, Inc.